JPS5569510A - Carcinostatic agent - Google Patents

Carcinostatic agent

Info

Publication number
JPS5569510A
JPS5569510A JP14168378A JP14168378A JPS5569510A JP S5569510 A JPS5569510 A JP S5569510A JP 14168378 A JP14168378 A JP 14168378A JP 14168378 A JP14168378 A JP 14168378A JP S5569510 A JPS5569510 A JP S5569510A
Authority
JP
Japan
Prior art keywords
carcinostatic agent
chlorobenzaldehyde
fluorobenzaldehyde
nitrobenzaldehyde
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP14168378A
Other languages
Japanese (ja)
Inventor
Kenji Sakaguchi
Jiyan.Riyutsuku.Tsunderu
Tokichi Miyagawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Priority to JP14168378A priority Critical patent/JPS5569510A/en
Publication of JPS5569510A publication Critical patent/JPS5569510A/en
Pending legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

PURPOSE: To provide a carcinostatic agent effective to the scirrhous cancer, containing at least one benzaldehyde derivative selected from p-nitrobenzaldehyde, p- fluorobenzaldehyde and m-chlorobenzaldehyde.
CONSTITUTION: A composition containging at least one benzaldehyde derivative selected from p-nitrobenzaldehyde, p-fluorobenzaldehyde and m-chlorobenzaldehyde. Administered by intravenous injection, subcutaneous injection, or oral administration in the form of a capsule. Dose: 5W100mg/kg for adult as an aqueous solution (for injection), and 20W500mg/kg by oral administration.
COPYRIGHT: (C)1980,JPO&Japio
JP14168378A 1978-11-16 1978-11-16 Carcinostatic agent Pending JPS5569510A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14168378A JPS5569510A (en) 1978-11-16 1978-11-16 Carcinostatic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14168378A JPS5569510A (en) 1978-11-16 1978-11-16 Carcinostatic agent

Publications (1)

Publication Number Publication Date
JPS5569510A true JPS5569510A (en) 1980-05-26

Family

ID=15297771

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14168378A Pending JPS5569510A (en) 1978-11-16 1978-11-16 Carcinostatic agent

Country Status (1)

Country Link
JP (1) JPS5569510A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007479A2 (en) * 1992-10-01 1994-04-14 The Wellcome Foundation Limited Immunopotentiatory agents
JP2017506665A (en) * 2014-02-26 2017-03-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Nitrobenzaldehyde proton release method for manipulation of cellular acidosis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007479A2 (en) * 1992-10-01 1994-04-14 The Wellcome Foundation Limited Immunopotentiatory agents
WO1994007479A3 (en) * 1992-10-01 1994-07-21 Wellcome Found Immunopotentiatory agents
JP2017506665A (en) * 2014-02-26 2017-03-09 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Nitrobenzaldehyde proton release method for manipulation of cellular acidosis
CN107073119A (en) * 2014-02-26 2017-08-18 德克萨斯大学***董事会 Release for the nitrobenzaldehyde proton of manipulation cell acid poisoning
US10946096B2 (en) 2014-02-26 2021-03-16 The Board Of Regents Of The University Of Texas System Nitrobenzaldehyde proton release for manipulation of cellular acidosis

Similar Documents

Publication Publication Date Title
JPS5225013A (en) Insulin pharmaceutical for nasal administration
JPS5551020A (en) Remedy for rheumatism
JPS5332124A (en) Carcinostatic agent
JPS56138111A (en) Suppository containing unsaturated fatty acid or salt thereof
JPS57109721A (en) Carcinostatic agent
JPS52108028A (en) Remedies for dysacousis
JPS5569510A (en) Carcinostatic agent
JPS5630917A (en) Preventive and remedy for hepatitis
JPS56138110A (en) Suppository containing citric acid or salt thereof
JPS5470428A (en) Carcinostatic agent
JPS56115715A (en) Physiologically active agent containing (3- dimethylcarbam-oxyphenyl) trimethyl ammonium derivative
JPS53148518A (en) Stabilized prostaglandin e composition and its preparation
JPS57114512A (en) Antidia beticagent comprising (3-dimethyl-carbamoxy- phenyl)trimethyl ammonium derivative
JPS55122721A (en) Antidiabetic agent
JPS54132239A (en) Anti-tumor agent
JPS56138112A (en) Suppository containing ascorbic acid or sodium ascorbate
JPS5675428A (en) Hypoglycemic agent containing procainamide hydrochloride
JPS5498339A (en) Carcinostatic agent
JPS5484034A (en) Anti-tumor agent
JPS54125663A (en) Carcinostatic agent and novel compound having carcinostatic activity
JPS51136818A (en) Method for preparing stable prostaglandine pharma ceuticals
JPS5251362A (en) Preparation of optically active pyrrolidine derivatives
JPS52130906A (en) Stable solution of uracil derivative
JPS57126422A (en) Stabilizing method of lysozyme pharmaceutical
JPS5742620A (en) Novel antiulcer agent